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Despite the many neuroimaging studies that suggest gray
matter volume reductions in schizophrenia, there is no com-
pelling postmortem evidence to suggest neuronal loss, nor
is there a distinctive or speciﬁc signature of gray matter
abnormalities in schizophrenia. Instead, there appears to be
no observed focal lesion that characterizes gray matter
pathology in schizophrenia. This state of aﬀairs has led to
a movement away from conceptualizing schizophrenia as
resulting from a single lesion, to conceptualizing schizophre-
nia as arising from abnormal communication between brain
regions. Abnormal connectivity between brain regions is not
a new concept, as Bleuler (1911) postulated such abnormal-
ities. What is new, however, is an appreciation that brain
regions that are not spatially proximal may be connected
functionally into neural networks and that to understand
altered neural connectivity we need to have a better under-
standing of the connections between brain regions which
are made possible by white matter, the main infrastructure
in the brain that makes possible long distance commu-
nication among neurons. Accordingly, a focus on white
matter connections in the brain has become increasingly of
interest in schizophrenia, particularly in the areas of imaging
studies, postmortem studies, and new animal models of
schizophrenia. This special issue focuses on schizophrenia
and oligodendrocytes, the latter a class of neuroglia that give
r i s et om y e l i n .T h ep r i m a r ya i mo ft h i ss p e c i a li s s u ei st o
understand and to clarify further white matter pathology in
schizophrenia and how it may contribute to disconnectivity
amongbrainregions,whichresultsintheobservedcognitive,
behavioral, and clinical symptoms in this disorder.
The ﬁrst paper begins with a description of the theory
that schizophrenia reﬂects a disorder of connectivity. The
proposition put forth is that schizophrenia is, at least in
part, the result of abnormal communication between brain
regions that may be spatially distant but nonetheless func-
tionally connected. As white matter is the main infrastruc-
ture for brain connectivity, this paper focuses on the use
of a magnetic resonance imaging (MRI) technique called
diﬀusion tensor imaging (DTI) to gain insight into the role
of white matter abnormalities in schizophrenia. This paper
also focuses on the functional implications of white matter
abnormalities, particularly with regard to the possible role
of myelin in modulating the transmission velocity of neural
discharges. The paper ends with a speculative hypothesis
about the relationship between gray matter and white matter
abnormalities in schizophrenia.
The second paper also focuses on altered neuronal con-
nectivity. Here, however, the focus is on altered connec-
tivity and impaired myelination in a postmortem study of
schizophrenia and normal controls, where electron micros-
copyisusedtostudymyelinatedﬁbersandoligodendrocytes.
This morphometric study examines myelinated ﬁbers in the
prefrontal cortex in both gray and white matter. Six types of
abnormal ﬁbers and ultrastructural alterations are described
in the schizophrenia sample. The study reveals increased
pathological ﬁbers in gray matter in both young and elderly
patients that are associated with positive symptoms, while in
elderly patients, the frequency of pathological ﬁbers in white
matter is increased and these changes are associated with
more negative symptoms. The key implication here is that2 Schizophrenia Research and Treatment
altered myelinated ﬁbers in white matter in schizophrenia
likely follow alterations of myelinated ﬁbers in gray matter
that occur earlier in the course of illness.
The third paper is a postmortem study on age-related
changesinthenumberofoligodendrocytesinprefrontalcor-
tex in schizophrenia, bipolar disorder and major depression.
The study reveals an age-related increase in numerical den-
sityofoligodendrocytesinlayerVIandadjacentwhitematter
of BA9 and 10 that is seen only in normal controls and not
in schizophrenia or in mood disorders. The absence of the
normal age-related increase in oligodendrocytes in patients
suggests that this aspect of normal brain development is
dysregulated in schizophrenia and in mood disorders, and
conﬁrmspostmortemandimagingdata,furtherhighlighting
the fact that the absence of a normal age-related increase in
oligodendrocytes is a key shared feature in these psychiatric
populations.
The fourth paper reviews white matter abnormalities in
schizophrenia, including imaging and postmortem ﬁndings
on the disconnectivity theory of schizophrenia, a major
theme that underlies the three previous papers in this special
issue. This paper then reviews some of the white mat-
ter diseases that commonly lead to psychotic symptoms
and then reviews transgenic and mutant mouse models of
schizophrenia. More speciﬁcally, genetic mouse models such
as Plp1 transgenic mice and mutant mice heterogeneous
for either NRG1 or its receptor erbB4, as well as Nogo-A-
deﬁcient mice are reviewed. This is followed by a focus on
the myelin toxicity model of mice fed cuprizone. In the early
stage (the second and third week) of the cuprizone feeding,
miceshowhigherdopaminelevelsandlowernorepinephrine
levels in their prefrontal cortex, along with behavioral
changes indicative of increased CNS activity. In the late
stage (weeks 4–6), when demyelination and oligodendrocyte
loss are obvious, mice display cognitive deﬁcits as well as
deﬁcits in social interactions that are reminiscent of social
withdrawal seen in patients with schizophrenia. Importantly,
this cuprizone-feeding mouse may be used as an in vivo
platform for psychopharmacological studies testing the ef-
fects of antipsychotic drugs on white matter alterations and
associatedbehavioralchanges,inadditiontoprovidinganew
animal model of schizophrenia.
The ﬁfth and ﬁnal paper of this special issue focuses on
abnormal behavior and microstructural changes in juvenile
mice that are repeatedly exposed to nonneurotoxic levels
of amphetamine. These mice are compared with nonam-
phetaminetreatedmice.Oligodendrocytenumbersandthree
proteins expressed in mature oligodendrocytes are investi-
gated in these young male mice at sacriﬁce. Treated mice
showed higher locomotion and impaired spatial working
memory, along with lowered Noga-A and GST-pi proteins,
and lower MBP proteins, in frontal cortex and hippocampus
andfewermatureoligodendrocytesinfrontalcortexandcor-
pus callosum,as well as lower MBPstaining in frontal cortex,
corpus callosum, and hippocampus, than untreated mice.
These diﬀerences suggest that in wild-type mice late devel-
oping white matter is vulnerable to amphetamine and may
lead to compromised white matter with increased dopamine
in speciﬁc brain regions. Not only do these ﬁndings explain
well the increased locomotion and impaired spatial working
memory observed in amphetamine-treated mice, but also
may serve as a principle for the amphetamine-treated mouse
being used as a novel animal model of schizophrenia.
To summarize, compared to the focus on gray matter
and neurons, research on white matter and myelin/glial has
been sparse in schizophrenia. In this special issue, neu-
roimaging ﬁndings are presented that suggest that myelin
abnormalities in schizophrenia may underlie the white mat-
ter abnormalities observed using diﬀusion tensor imaging
techniques. Data from postmortem studies also conﬁrm the
presence of oligodendrocyte and myelin abnormalities in
schizophrenia as well as mood disorders. Oligodendrocytes
provide protection and improve communication between
brain regions and the oligodendroglia-producing myelin
is approaching maturity in the same time frame as the
onsetofsymptoms.Further,normalage-relatedwhitematter
increases and related gray matter changes that likely predate
the white matter changes are dysregulated in schizophrenia
and may contribute to the clinical symptomatology of the
disease. Finally, the recently developed animal models are
notonlyofhelpinunderstandingconnectivityabnormalities
in schizophrenia but also provide novel platforms to test
novel therapeutic approaches for schizophrenic patients.
Treatments speciﬁcally targeting white matter, for example,
may improve on the eﬃcacy of those treatments currently in
use.
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